|
1
|
Zappa C and Mousa SA: Non-small cell lung
cancer: Current treatment and future advances. Transl Lung Cancer
Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Borsig L, Wolf MJ, Roblek M, Lorentzen A
and Heikenwalder M: Inflammatory chemokines and metastasis-Tracing
the accessory. Oncogene. 33:3217–3224. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu W, Jiang L, Bian C, Liang Y, Xing R,
Yishakea M and Dong J: Role of CX3CL1 in diseases. Arch Immunol
Ther Exp. 64:371–383. 2016. View Article : Google Scholar
|
|
4
|
Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J,
Gonzalo JA, Vath J, Gosselin M, Ma J, Dussault B, et al:
Neurotactin, a membrane-anchored chemokine upregulated in brain
inflammation. Nature. 387:611–617. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bazan JF, Bacon KB, Hardiman G, Wang W,
Soo K, Rossi D, Greaves DR, Zlotnik A and Schall TJ: A new class of
membrane-bound chemokine with a CX3C motif. Nature. 385:640–644.
1997. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Julia V, Staumont-Salle D and Dombrowicz
D: Role of fractalkine/CX3CL1 and its receptor CX3CR1 in allergic
diseases. Med Sci (Paris). 32:260–266. 2016.(Article in French).
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thomas S and Baumgart DC: Targeting
leukocyte migration and adhesion in Crohn's disease and ulcerative
colitis. Inflammopharmacology. 20:1–18. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yoneda O, Imai T, Goda S, Inoue H,
Yamauchi A, Okazaki T, Imai H, Yoshie O, Bloom ET, Domae N and
Umehara H: Fractalkine-mediated endothelial cell injury by NK
cells. J Immunol. 164:4055–4062. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gu X, Tang XD, Gu SY, Yang SQ, Zhou PJ and
Tan JM: Expression of fractalkine and its receptor in acute cardiac
allografts rejection. Zhonghua wai ke za zhi. 41:139–142. 2003.(In
Chinese). PubMed/NCBI
|
|
10
|
Hyakudomi M, Matsubara T, Hyakudomi R,
Yamamoto T, Kinugasa S, Yamanoi A, Maruyama R and Tanaka T:
Increased expression of fractalkine is correlated with a better
prognosis and an increased number of both CD8+ T cells and natural
killer cells in gastric adenocarcinoma. Ann Surg Oncol.
15:1775–1782. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ohta M, Tanaka F, Yamaguchi H, Sadanaga N,
Inoue H and Mori M: The high expression of Fractalkine results in a
better prognosis for colorectal cancer patients. Int J Oncol.
26:41–47. 2005.PubMed/NCBI
|
|
12
|
Gaudin F, Nasreddine S, Donnadieu AC,
Emilie D, Combadière C, Prévot S, Machelon V and Balabanian K:
Identification of the chemokine CX3CL1 as a new regulator of
malignant cell proliferation in epithelial ovarian cancer. PLoS
One. 6:e215462011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim M, Rooper L, Xie J, Kajdacsy-Balla AA
and Barbolina MV: Fractalkine receptor CX(3)CR1 is expressed in
epithelial ovarian carcinoma cells and required for motility and
adhesion to peritoneal mesothelial cells. Mol Cancer Res. 10:11–24.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li F, Wang Z, Liu Y and Li J:
Down-regulation of fractalkine inhibits the in vitro and in vivo
angiogenesis of the hepatocellular carcinoma HepG2 cells. Oncol
Rep. 24:669–675. 2010.PubMed/NCBI
|
|
15
|
Andre F, Cabioglu N, Assi H, Sabourin JC,
Delaloge S, Sahin A, Broglio K, Spano JP, Combadiere C, Bucana C,
et al: Expression of chemokine receptors predicts the site of
metastatic relapse in patients with axillary node positive primary
breast cancer. Ann Oncol. 17:945–951. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jamieson-Gladney WL, Zhang Y, Fong AM,
Meucci O and Fatatis A: The chemokine receptor CX(3)CR1 is directly
involved in the arrest of breast cancer cells to the skeleton.
Breast Cancer Res. 13:R912011. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rousseaux S, Debernardi A, Jacquiau B,
Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY,
Lantuejoul S, Hainaut P, et al: Ectopic activation of germline and
placental genes identifies aggressive metastasis-prone lung
cancers. Sci Transl Med. 5:186ra1662013. View Article : Google Scholar
|
|
19
|
Botling J, Edlund K, Lohr M, Hellwig B,
Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Pontén F, et
al: Biomarker discovery in non-small cell lung cancer: Integrating
gene expression profiling, meta-analysis, and tissue microarray
validation. Clin Cancer Res. 19:194–204. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tang H, Xiao G, Behrens C, Schiller J,
Allen J, Chow CW, Suraokar M, Corvalan A, Mao J, White MA, et al: A
12-gene set predicts survival benefits from adjuvant chemotherapy
in non-small cell lung cancer patients. Clin Cancer Res.
19:1577–1586. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Der SD, Sykes J, Pintilie M, Zhu CQ,
Strumpf D, Liu N, Jurisica I, Shepherd FA and Tsao MS: Validation
of a histology-independent prognostic gene signature for
early-stage, non-small-cell lung cancer including stage IA
patients. J Thorac Oncol. 9:59–64. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shedden K, Taylor JM, Enkemann SA, Tsao
MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ,
Misek DE, et al: Gene expression-based survival prediction in lung
adenocarcinoma: A multi-site, blinded validation study. Nat Med.
14:822–827. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu CQ, Ding K, Strumpf D, Weir BA,
Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, et
al: Prognostic and predictive gene signature for adjuvant
chemotherapy in resected non-small-cell lung cancer. J Clin Oncol.
28:4417–4424. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Budczies J, Klauschen F, Sinn BV, Győrffy
B, Schmitt WD, Darb-Esfahani S and Denkert C: Cutoff Finder: A
comprehensive and straightforward web application enabling rapid
biomarker cutoff optimization. PLoS One. 7:e518622012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yao X, Qi L, Chen X, Du J, Zhang Z and Liu
S: Expression of CX3CR1 associates with cellular migration,
metastasis, and prognosis in human clear cell renal cell carcinoma.
Urol Oncol. 32:162–170. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Johnson LA and Jackson DG: The chemokine
CX3CL1 promotes trafficking of dendritic cells through inflamed
lymphatics. J Cell Sci. 126:5259–5270. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Umehara H, Bloom ET, Okazaki T, Nagano Y,
Yoshie O and Imai T: Fractalkine in vascular biology: From basic
research to clinical disease. Arterioscler Thromb Vasc Biol.
24:34–40. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fong AM, Robinson LA, Steeber DA, Tedder
TF, Yoshie O, Imai T and Patel DD: Fractalkine and CX3CR1 mediate a
novel mechanism of leukocyte capture, firm adhesion, and activation
under physiologic flow. J Exp Med. 188:1413–1419. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Park MH, Lee JS and Yoon JH: High
expression of CX3CL1 by tumor cells correlates with a good
prognosis and increased tumor-infiltrating CD8+ T cells, natural
killer cells, and dendritic cells in breast carcinoma. J Surg
Oncol. 106:386–392. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jamieson WL, Shimizu S, D'Ambrosio JA,
Meucci O and Fatatis A: CX3CR1 is expressed by prostate epithelial
cells and androgens regulate the levels of CX3CL1/fractalkine in
the bone marrow: Potential role in prostate cancer bone tropism.
Cancer Res. 68:1715–1722. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shulby SA, Dolloff NG, Stearns ME, Meucci
O and Fatatis A: CX3CR1-fractalkine expression regulates cellular
mechanisms involved in adhesion, migration, and survival of human
prostate cancer cells. Cancer Res. 64:4693–4698. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Marchesi F, Piemonti L, Fedele G, Destro
A, Roncalli M, Albarello L, Doglioni C, Anselmo A, Doni A, Bianchi
P, et al: The chemokine receptor CX3CR1 is involved in the neural
tropism and malignant behavior of pancreatic ductal adenocarcinoma.
Cancer Res. 68:9060–9069. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou B, Xu H, Ni K, Ni X and Shen J:
Expression of chemokine XCL2 and CX3CL1 in lung cancer. Med Sci
Monit. 22:1560–1565. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Locatelli M, Boiocchi L, Ferrero S,
Martinelli Boneschi F, Zavanone M, Pesce S, Allavena P, Maria Gaini
S, Bello L and Mantovani A: Human glioma tumors express high levels
of the chemokine receptor CX3CR1. Eur Cytokine Netw. 21:27–33.
2010.PubMed/NCBI
|
|
35
|
Erreni M, Solinas G, Brescia P, Osti D,
Zunino F, Colombo P, Destro A, Roncalli M, Mantovani A, Draghi R,
et al: Human glioblastoma tumours and neural cancer stem cells
express the chemokine CX3CL1 and its receptor CX3CR1. Eur J Cancer.
46:3383–3392. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sciume G, Soriani A, Piccoli M, Frati L,
Santoni A and Bernardini G: CX3CR1/CX3CL1 axis negatively controls
glioma cell invasion and is modulated by transforming growth
factor-β1. Neuro Oncol. 12:701–710. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vitale S, Cambien B, Karimdjee BF, Barthel
R, Staccini P, Luci C, Breittmayer V, Anjuère F, Schmid-Alliana A
and Schmid-Antomarchi H: Tissue-specific differential antitumour
effect of molecular forms of fractalkine in a mouse model of
metastatic colon cancer. Gut. 56:365–372. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xin H, Kanehira M, Mizuguchi H, Hayakawa
T, Kikuchi T, Nukiwa T and Saijo Y: Targeted delivery of CX3CL1 to
multiple lung tumors by mesenchymal stem cells. Stem Cells.
25:1618–1626. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Erreni M, Siddiqui I, Marelli G, Grizzi F,
Bianchi P, Morone D, Marchesi F, Celesti G, Pesce S, Doni A, et al:
The fractalkine-receptor axis improves human colorectal cancer
prognosis by limiting tumor metastatic dissemination. J Immunol.
196:902–914. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Matsubara T, Ono T, Yamanoi A, Tachibana M
and Nagasue N: Fractalkine-CX3CR1 axis regulates tumor cell cycle
and deteriorates prognosis after radical resection for
hepatocellular carcinoma. J Surg Oncol. 95:241–249. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Marchesi F, Locatelli M, Solinas G, Erreni
M, Allavena P and Mantovani A: Role of CX3CR1/CX3CL1 axis in
primary and secondary involvement of the nervous system by cancer.
J Neuroimmunol. 224:39–44. 2010. View Article : Google Scholar : PubMed/NCBI
|
